All In Biotech

Drug Trial Radar · NCT05968885

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 1, 2021

Primary completion

Jun 30, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Mackay Memorial HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 20 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.

Conditions

  • Urinary Bladder, Overactive
  • Urodynamics
  • Effect of Drug

Interventions

  • Intradetrusor Botox® (onabotulinumtoxinA) injectionProcedure

    The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.

  • Combine Mirabegron and Solifenacin.Drug

    Combination pharmacotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short form of Urinary Distress Inventory (UDI-6)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
  2. Short form of Incontinence Impact Questionnaire (IIQ-7)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment
  3. Overactive Bladder Symptom Score (OABSS)Time frame: Assess before treatment and 1 month, 3 months, 6 months and 1 year after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mackay Memorial Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.